Syneos Health Signs Agreement With Aotearoa Clinical Trials, Further Expanding Catalyst Site Program In New Zealand
Syneos Health® (NASDAQ:SYNH) a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Aotearoa Clinical Trials, expanding the Company’s clinical trial capabilities across a broad range of therapeutic areas in New Zealand, including Oncology, General Medicine and Vaccines.
Aotearoa Clinical Trials now joins the Syneos Health Catalyst Site Program, which was introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery.
Together, Syneos Health and Aotearoa Clinical Trials will enable sites, sponsors and patients to collaborate in multiple therapeutic areas, fueling engagement through transparent communication channels during the entire clinical trial process.
“Our work with Aotearoa Clinical Trials enables us to provide customized solutions that address our customers’ unique and complex needs,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “We look forward to collaborating with Aotearoa Clinical Trials as part of the Catalyst Site Program.”
Syneos Health has relationships with more than 100 Catalyst sites worldwide and the Company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships.
Dr. Edward Watson CEO at Aotearoa Clinical Trials welcomed the signature of the agreement: “We are excited to be part of the Catalyst Site Program which will enable more clinical trials to be performed in New Zealand and provide more options for clinical trial participation in our communities.”